MHRA renews EAMS scientific opinion for Puldysa in DMD
The drug has been available in the UK through EAMS since June 2017.
Read Moreby Anna Smith | Jun 24, 2019 | News | 0
The drug has been available in the UK through EAMS since June 2017.
Read Moreby Anna Smith | Feb 25, 2019 | News | 0
Santhera Pharmaceuticals has announced results from its Syros DMD study.
Read Moreby Selina McKee | Jun 22, 2018 | News | 0
UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme (EAMS) for another year.
Read Moreby Selina McKee | Mar 6, 2018 | News | 0
Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.
Read Moreby Selina McKee | Jan 29, 2018 | News | 0
Santhera’s attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors.
Read Moreby Selina McKee | Jun 22, 2017 | News | 0
Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS).
Read Moreby Selina McKee | May 9, 2017 | News | 0
The Scottish Medicines Consortium has endorsed three medicines for routine use by NHS Scotland, offering new options to treat a rare eye disease, lupus and infertility.
Read Moreby Selina McKee | Jun 22, 2016 | News | 0
European regulators have validated Santhera’s marketing application for Raxone as a treatment for certain patients with Duchenne muscular dystrophy.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479